Simon J. Crabb

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy

Roland Seiler, H.A.D.M. Ashab, Nicholas Erho et al. · European Urology · 2017 · 792 citations

Medicine, Oncology, Urology +13

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

Joaquı́n Mateo, Núria Porta, Diletta Bianchini et al. · The Lancet Oncology · 2019 · 644 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

Thomas Powles, Mark Kockx, Alejo Rodríguez‐Vida et al. · Nature Medicine · 2019 · 571 citations · Full text

Medicine, Oncology, Urology +13

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

Kenneth J. Pienta, Jean-Pascal Machiels, Dirk Schrijvers et al. · Investigational New Drugs · 2012 · 399 citations

Medicine, Oncology, Pharmacology +17